All sixteen Phase III
trials with indiplon have demonstrated positive results, making this one of
the most solid clinical evaluations of any new drug candidate ," said Dr.

imperforate pruritus

neurocrine.com. Patients received nightly
administration of 15 mg of indiplon MR tablets or placebo over a four-week
period. news releases are
available through the Company's website via the Internet at
http://www.

anorectal irritable

Study Design
The study was a randomized, double -blind, placebo-controlled,
parallel-group, multi-center, out-patient Phase III clinical trial conducted
in 248 adult patients with sleep maintenance difficulties.

intracranial hypotension

Neurocrine Biosciences, Inc .S.

indigestion intermittent

is a product-based biopharmaceutical company
focused on neurological and endocrine diseases and disorders.

cystitis incontinentia

Viewers are encouraged to visit the website approximately 5 minutes prior to
the presentation to download or install any necessary software. Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia, anxiety, depression, diabetes, multiple sclerosis ,
irritable bowel syndrome, eating disorders, pain, and autoimmunity.
"These results once again confirmed the robustness, consistency, clinical
relevance and safety profile of the data for indiplon . Neurocrine Biosciences, Inc.

incontinentia genitourinary

The live presentation will take place at 2:50 p. is a product -based biopharmaceutical company
focused on neurological and endocrine diseases and disorders.

uveitis bowel

news releases are available through the Company's
website via the Internet at http://www.

Contact: Claudia Woodworth or Elizabeth Foster at 858-617-7600. SAN DIEGO, Neurocrine Biosciences, Inc.

intestinal isaacs

Neurocrine Reports Positive Phase III Efficacy and Safety Results With Indiplon Modified Release (MR) Tablets in Treating Adult Patients With Chronic Insomnia

cystitis interstitial

The study was
conducted at 50 sleep centers in the U. Specifically, the risks and
uncertainties the Company faces with respect to its indiplon program include,
but are not limited to; risk that the Company will not be able to reformat the
indiplon IR and/or MR NDA within the Company's projected timelines; risk that
the Company will be unable to reformat the indiplon IR and/or MR NDA in a
manner acceptable to the FDA; the risk that regulatory authorities may reject
our regulatory submissions or find them incomplete or insufficient; risk that
additional clinical studies may be required to support submissions for
regulatory approval; risk that the indiplon labeling granted by regulatory
authorities may limit the commercial success of indiplon; risk relating to the
Company's dependence on contract manufacturers for clinical drug supply and
compliance with regulatory requirements for marketing approval; risks
associated with the Company's dependence on corporate collaborators for
commercial manufacturing and marketing and sales activities; uncertainties
relating to patent protection and intellectual property rights of third
parties; risks and uncertainties relating to competitive products and
technological changes that may limit demand for the Company's products; risk
that the Company will be unable to raise additional funding required to
complete development of all of its product candidates; and the other risks
described in the Company's report on Form 10-K for the year ended December 31,
2003 and most recent report on Form 10-Q filed for the quarter ended,
September 30, 2004.

pruritus intestinal

If you are unable to attend the webcast and would like further information
on this announcement please contact the Investor Relations Department at
Neurocrine Biosciences at (858) 617-7600 and ask for Claudia Woodworth or
Elizabeth Foster. Our product
candidates address some of the largest pharmaceutical markets in the world
including insomnia, certain female and male disorders, anxiety, depression,
diabetes, multiple sclerosis, irritable bowel syndrome, eating disorders,
pain, and autoimmunity.

genitourinary iritis

0002) over the four-weeks of treatment.

Patients receiving
indiplon gained approximately one hour of sleep over baseline.

About Indiplon
Indiplon is a unique non-benzodiazapine agent that acts on a specific site
of the GABA-A receptor.

anorectal isaacs

pigmenti uveitis

m. Henry
Pan, Executive Vice President and Chief Medical Officer for Neurocrine
Biosciences. Two formulations of indiplon, IR capsules
and MR tablets, are being evaluated in clinical trials to address different
types of sleep problems.

Neurocrine Biosciences , Inc.

pruritus anorectal

(Nasdaq: NBIX), a biopharmaceutical company focused on neurological and
endocrine diseases and disorders, announced today that Gary Lyons, President
and CEO, will present at the 12th Annual NewsMakers in the Biotech Industry
Conference at the Sheraton New York Hotel + Towers on Friday, September 9,
2005.
Neurocrine Biosciences, Inc.

interstitial pruritus

Company Presentation and Webcast on Friday , September 9, 2005

SAN DIEGO, Neurocrine Biosciences, Inc. Pacific Daylight Time (PDT) and will include marketing
highlights for indiplon as well as an update on the Company's broad
development pipeline and research programs. "As we had seen with the same measurements in our previous
elderly study, the 15-mg dose showed significant improvement in sleep
maintenance at every primary and secondary endpoint, as well as in next day
functioning and alertness in this adult patient population.

irritable interstitial

The presentation will be webcast
and can be accessed on the Company's website at http://www.

iga hypotension

Eastern Daylight Time
(EDT) / 11:50 a.com

In addition to historical facts, this press release may contain
forward-looking statements that involve a number of risks and uncertainties.

pruritus incontinentia

A replay of the webcast will be available approximately one hour after the
presentation concludes and will be archived until Friday, September 23, 2005.com. Safety results
were consistent with those previously reported in other Phase III indiplon
studies. Neurocrine expects to
submit an NDA for indiplon MR in the 2nd Quarter of 2005 that will include the
results of this trial.

hymen cystitis

Neurocrine Biosciences to Present at the BioCentury Annual NewsMakers in the Biotech Industry Conference

Approximately 35 percent of the adult population reports
that they have experienced insomnia every night or almost every night within
the past year. Neurocrine undertakes no obligation to update the
statements contained in this press release after the date hereof.

uveitis indigestion

uveitis intrauterine

Efficacy results with indiplon MR tablets demonstrated a
highly statistically significant and clinically relevant improvement on the
primary endpoint of patient reported Total Sleep Time (sTST) as compared to
placebo (p=0. Indiplon has been shown to bind selectively to the
specific subtype of GABA-A receptors within the brain believed to be
responsible for promoting sleep.

Insomnia is a prevalent condition in the United States, with approximately
40 percent of the adult population reporting trouble sleeping a few nights per
week or more, according to the National Sleep Foundation's (NSF) Sleep in
America Poll 2002.

imperforate nephropathy

The endpoints in this trial were the same as those studied in our
elderly trial utilizing the 15 mg dose.

cystitis isaacs

neurocrine.
(Nasdaq: NBIX) today announced indiplon MR 15-mg tablets demonstrated
statistically significant improvement for all primary and secondary endpoints
in the Company's Phase III clinical trial involving 248 adult patients with
chronic insomnia. More importantly,
this study also demonstrated favorable patient and investigator reported
outcomes as well as in quality of life improvement. We believe the registration of indiplon MR and IR will
provide a broad spectrum of treatment for all sleep difficulties including
sleep initiation, and sleep maintenance, and long term chronic usage," added
Pan.

anorectal nephropathy

Indiplon was licensed from DOV Pharmaceutical in
1998. Insomnia remains a disorder with high unmet medical needs,
including prolonged awakenings during the night with difficulty falling back
to sleep.neurocrine.
Among the factors that could cause actual results to differ materially from
those indicated in the forward looking statements are risks and uncertainties
associated with Neurocrine's business and finances in general including, but
not limited to, risk and uncertainties associated with the Company's indiplon
program and planned regulatory activities .

interstitial genitourinary